ArticleThe American journal of managed care2012
Racial disparities in lipid control in patients with diabetes.
Article in The American journal of managed care, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Prognostic value of the triglyceride-glucose (TyG) index for renal function progression in patients with CKD stages 3-4.Frontiers in nutrition · 2026Article
- Leveraging Healthcare System Data to Identify High-Risk Dyslipidemia Patients.Current cardiology reports · 2022Review
- Missed opportunities in medical therapy for patients with heart failure in an electronically-identified cohort.BMC cardiovascular disorders · 2022Article
- Optimizing treatment goals for long-term health outcomes among patients with type 2 diabetes mellitus.BMJ open diabetes research & care · 2021Article
- Interventions to Reduce Ethnic and Racial Disparities in Dyslipidemia Management.Current treatment options in cardiovascular medicine · 2019Review
- Examining Factors Associated With Nonadherence And Identifying Providers Caring For Nonadherent Subgroups.Journal of pharmaceutical health services research : an official journal of the Royal Pharmaceutical Society of Great Britain · 2017Article
- Medication Adherence Does Not Explain Black-White Differences in Cardiometabolic Risk Factor Control among Insured Patients with Diabetes.Journal of general internal medicine · 2016Article
- Racial comparisons of diabetes care and intermediate outcomes in a patient-centered medical home.Diabetes care · 2014Article
- Medication adherence in patients with diabetes and dyslipidemia: associated factors and strategies for improvement.Current cardiology reports · 2013Review
- Factors Influencing the Increasing Disparity in LDL Cholesterol Control Between White and Black Patients With Diabetes in a Context of Active Quality Improvement.American journal of medical quality : the official journal of the American College of Medical QualityArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectivesTo describe lipid management over time in a cohort of insured patients with diabetes and evaluate differences between African American and white patients. STUDY
designAutomated claims data were used to identify a cohort of 11,411 patients with diabetes in 1997 to 1998. Patients were followed through 2007.
methodsRates of hypercholesterolemia testing, treatment, and goal attainment were measured annually. Treatment was determined by a claim for lipid-lowering agents, and goal attainment was defined as a low-density lipoprotein cholesterol (LDL-C) level <100 mg/dL.
resultsDuring the study period, LDL-C testing increased from 48% to 70% among African American patients and from 61% to 77% among white patients. Treatment with lipid-lowering drugs increased from 23% to 56% among African American patients and 33% to 61% among white patients. The proportion at goal increased from 35% to 76% and from 24% to 59% among white and African American patients, respectively. African American patients were less likely to be tested for LDL-C (odds ratio [OR] 0.79; 95% confidence interval [CI] 0.73-0.86), treated with lipidlowering agents (OR 0.72; 95% CI 0.65-0.80), have their medication dosage altered (OR 0.65; 95% CI 0.59-0.73), or attain LDL-C goal (OR 0.59; 95% CI 0.56-0.63) compared with white patients.
conclusionsAlthough rates of LDL-C testing, treatment, and goal attainment improved over time, racial disparities in dyslipidemia management continued to exist. Further studies to determine the causes of differences in management by race are warranted.
Indexed as
Identifiers
22774998PMC3766626What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.